TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07216560: First-in-human Study of 7MW4911 in GI Cancer

Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 200 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT07216560 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07216560 Rescue Dossier →